SARS-CoV-2 IgM Quantitative ELISA Kit (DEIASL020Q)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Serum, plasma
Species Reactivity
Intended Use
This kit is used for the quantitative detection of novel coronavirus IgM antibodies in human serum or plasma in vitro.
This kit is stored at 2 ~ 8 °C, the validity period is 6 months.
Avoid freezing and use within the validity period.
Detection Range
The detection range of this kit is 0.3125-5 ng/mL.
General Description
The new coronavirus belongs to the beta coronavirus of the genus β, which has an envelope, the particles are round or oval, often polymorphic, and the diameter is 60-140 nm. Its genetic characteristics are significantly different from SARSr-CoV and MERSr-CoV. Current research shows that it has more than 85% homology with bat SARS-like coronavirus (bat-SL- CoVZC45). In vitro isolation and culture, 2019-nCoV can be found in human respiratory epithelial cells in about 96 hours, while it takes about 6 days to isolate and culture in Vero E6 and Huh-7 cell lines. Based on current epidemiological investigations, the incubation period is generally 7 days, with a maximum of 14 days. Main symptoms are fever, fatigue, and dry cough. A few patients have symptoms such as nasal congestion, runny nose, and diarrhea. In severe cases, dyspnea occurs more than a week later. In severe cases, acute respiratory distress syndrome, septic shock, difficult to correct metabolic acidosis, and coagulation dysfunction develop rapidly. It is worth nothing that in the course of severe and critically ill patients, there may be moderate to low fever, even without obvious fever. Some patients showed only low fever, mild fatigue, and no pneumonia and recovered after 1 week. In the early stages of the disease, the total number of white blood cells in the peripheral blood was normal or decreased, the lymphocyte count decreased, and some patients had increased liver enzymes, muscle enzymes, and myoglobin. Most patients have elevated C- reactive protein (CRP) and erythrocyte sedimentation rate and normal procalcitonin. In severe cases, D-dimer increases and peripheral blood lymphocytes progressively decrease. New coronavirus nucleic acids can be detected in throat swabs, sputum, lower respiratory tract secretions, and blood. Serum antibody testing helps confirm the infection status of a case.


Have you cited DEIASL020Q in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Neuropathology of patients with COVID-19 in Germany: a post-mortem case series


Authors: Matschke, Jakob; Luetgehetmann, Marc; Hagel, Christian; Sperhake, Jan P.; Schroeder, Ann Sophie; Edler, Carolin; Mushumba, Herbert; Fitzek, Antonia; Allweiss, Lena; Dandri, Maura; Dottermusch, Matthias; Heinemann, Axel; Pfefferle, Susanne; Schwabenland, Marius; Magruder, Daniel Sumner; Bonn, Stefan; Prinz, Marco; Gerloff, Christian; Pueschel, Klaus; Krasemann, Susanne; Aepfelbacher, Martin; Glatzel, Markus

Background Prominent clinical symptoms of COVID-19 include CNS manifestations. However, it is unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, gains access to the CNS and whether it causes neuropathological changes. We investigated the brain tissue of patients who died from COVID-19 for glial responses, inflammatory changes, and the presence of SARS-CoV-2 in the CNS. Methods In this post-mortem case series, we investigated the neuropathological features in the brains of patients who died between March 13 and April 24, 2020, in Hamburg, Germany. Inclusion criteria comprised a positive test for SARS-CoV-2 by quantitative RT-PCR (qRT-PCR) and availability of adequate samples. We did a neuropathological workup including histological staining and immunohistochemical staining for activated astrocytes, activated microglia, and cytotoxic T lymphocytes in the olfactory bulb, basal ganglia, brainstem, and cerebellum. Additionally, we investigated the presence and localisation of SARS-CoV-2 by qRT-PCR and by immunohistochemistry in selected patients and brain regions. Findings 43 patients were included in our study. Patients died in hospitals, nursing homes, or at home, and were aged between 51 years and 94 years (median 76 years [IQR 70-86]). We detected fresh territorial ischaemic lesions in six (14%) patients. 37 (86%) patients had astrogliosis in all assessed regions. Activation of microglia and infiltration by cytotoxic T lymphocytes was most pronounced in the brainstem and cerebellum, and meningeal cytotoxic T lymphocyte infiltration was seen in 34 (79%) patients. SARS-CoV-2 could be detected in the brains of 21 (53%) of 40 examined patients, with SARS-CoV-2 viral proteins found in cranial nerves originating from the lower brainstem and in isolated cells of the brainstem. The presence of SARS-CoV-2 in the CNS was not associated with the severity of neuropathological changes. Interpretation In general, neuropathological changes in patients with COVID-19 seem to be mild, with pronounced neuroinflammatory changes in the brainstem being the most common finding. There was no evidence for CNS damage directly caused by SARS-CoV-2. The generalisability of these findings needs to be validated in future studies as the number of cases and availability of clinical data were low and no age-matched and sex-matched controls were included.

SARS-CoV-2 IgG antibody responses in New York City


Authors: Reifer, Josh; Hayum, Nosson; Heszkel, Benzion; Klagsbald, Ikey; Streva, Vincent A.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a strain of coronavirus that causes coronavirus disease 2019 (Covid-19) and has been declared a global pandemic by the World Health Organization. Total cases of SARS-CoV-2 worldwide exceed 10.2 million, with over 503,000 deaths recorded. Little is known about the body's immune response to SARS-CoV-2 infection. In this paper, we describe SARS-CoV-2 IgG antibody responses in 28,523 patients from the New York City metropolitan area and report a SARS-CoV-2 IgG positivity rate of 44%, indicating the widespread nature of the pandemic in the city and state of New York. Additionally, for a subset of patients, we report on the correlation between SARS-CoV-2 patient symptom severity and level of SARS-CoV-2 IgG antibody found in the patient sample. (C) 2020 The Author(s). Published by Elsevier Inc.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket